Warfarin

An anti-coagulant differs from (&minus)-warfarin by being five times less potent as a vitamin K antagonist has a longer terminal elimination half-life (35-58 hours) than (&minus)-warfarin (24-33 hours).

An anti-coagulant differs from (&minus)-warfarin by being five times less potent as a vitamin K antagonist has a longer terminal elimination half-life (35-58 hours) than (&minus)-warfarin (24-33 hours).

An anti-coagulant differs from (&minus)-warfarin by being five times less potent as a vitamin K antagonist has a longer terminal elimination half-life (35-58 hours) than (&minus)-warfarin (24-33 hours).

An anticoagulant differs from (+)-warfarin by being five times more potent as a vitamin K antagonist has a shorter terminal elimination half-life (24-33 hours) than (+)-warfarin (35-58 hours).

An anticoagulant differs from (+)-warfarin by being five times more potent as a vitamin K antagonist has a shorter terminal elimination half-life (24-33 hours) than (+)-warfarin (35-58 hours).

An anticoagulant differs from (+)-warfarin by being five times more potent as a vitamin K antagonist has a shorter terminal elimination half-life (24-33 hours) than (+)-warfarin (35-58 hours).

An anticoagulant differs from (+)-warfarin by being five times more potent as a vitamin K antagonist has a shorter terminal elimination half-life (24-33 hours) than (+)-warfarin (35-58 hours).

A racemic mixture of two optically active isomers, the R and S forms has a half-life of 36-42 hours in circulation, bound to plasma proteins, and accumulates in the liver, where the two isomers are metabolized by different pathways also used as a

10-Hydroxy warfarin β-D-glucuronide.

4′-Hydroxy Warfarin-d4 is a labelled metabolite of Warfarin in humans.

6-Hydroxy warfarin β-D-glucuronide.

6-Hydroxy warfarin β-D-glucuronide.